Nuhad Ibrahim, MD

Articles

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

Nuhad Ibrahim, MD;Sung-Bae Kim;Nancy U. Lin, MD;Ahmad Awada;Eva Ciruelos Gil;Alessandro Di Sanzo;Bartomeu Piza Vallespir;Kathy Puyana Theall;Erika P. Hamilton, MD

August 3rd 2024

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Erika P. Hamilton, MD;Lajos Pusztai, MD, DPhil;Hatem Soliman, MD;Sara A. Hurvitz, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Priya Marreddy;Tarek Sahmoud, MD;Nuhad Ibrahim, MD

April 28th 2023

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

Erika P. Hamilton, MD;Sung-Bae Kim;Neelima Vidula, MD;Simona Scartoni;Tarek Sahmoud, MD;Bartomeu Piza Vallespir;Kathy Puyana Theall;Nassir Habboubi;Nuhad Ibrahim, MD

April 27th 2023

Combinations of New and Old Agents for Breast Cancer Treatment: Future Directions

Gabriel N. Hortobagyi, MD, FACP;Nuhad Ibrahim, MD

June 1st 1996

Several new agents undergoing clinical development appear to be effective and tolerable in the management of metastatic breast cancer. In recent years, a number of new and exciting combinations have been described, with an efficacy similar or, in some cases, apparently superior to that of standard chemotherapeutic regimens, such as FAC and CMF. The next several years will witness a large number of comparative clinical trials, the major purpose of which will be to establish the role of these new drugs and combinations in the management of metastatic breast cancer. Almost simultaneously, similar strategies will be pursued for adjuvant therapy for primary breast cancer, with the goal of improving the curative efficacy of current regimens. These prospects are exciting; however, enthusiasm must be tempered with the knowledge that long-term toxicity is always a distinct possibility. Therefore, the development of new combinations, especially in the setting of adjuvant chemotherapy, should follow a systematic, conservative strategy. [ONCOLOGY 10(Suppl):30-36, 1996]